August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
FDA grants accelerated approval to Zenocutuzumab-zbco – The Babak Lab
Mar 18, 2025, 18:16

FDA grants accelerated approval to Zenocutuzumab-zbco – The Babak Lab

The Babak Lab shared a post on LinkedIn:

“FDA Grants Accelerated Approval to Zenocutuzumab-zbco (Bizengri).

On December 4th, 2024, the FDA granted accelerated approval to zenocutuzumab-zbco (Bizengri, Merus N.V.), marking a significant milestone for patients with NRG1 fusion-positive cancers. NRG1 gene fusions are rare but actionable drivers of cancer growth.

Until now, there were no approved therapies targeting this specific genetic alteration. This is the first FDA-approved systemic therapy specifically for:

  • ⁠Advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC) with NRG1 gene fusion, and
  • Advanced, unresectable, or metastatic pancreatic adenocarcinoma with NRG1 gene fusion.

Both indications are for patients who have experienced disease progression following prior systemic therapy.

Key Efficacy Data from the eNRGy Study:

The approval was based on results from the eNRGy study (NCT02912949), which evaluated 64 NSCLC and 30 pancreatic adenocarcinoma patients with NRG1 fusions:

  • NSCLC: Confirmed overall response rate (ORR) of 33%, with a median duration of response (DOR) of 7.4 months.
  • ⁠Pancreatic Adenocarcinoma: Confirmed ORR of 40%, with DOR ranging from 3.7 to 16.6 months.

For more details, click the following link.

Let’s celebrate this advancement and continue pushing the boundaries of cancer care!”

More posts featuring The Babak Lab.